Bristol-Myers Squibb Company (BMY.US), a leading pharmaceutical company, has filed its annual Form 11-K with the Securities and Exchange Commission for the fiscal year ended December 31, 2023. The report details the financial performance of the Bristol-Myers Squibb Company Employee Incentive Thrift Plan, which is a defined contribution retirement plan for its employees. The plan includes a variety of investment options and is subject to ERISA provisions. The financial statements, audited by Withum Smith + Brown, PC, indicate that the plan's net assets available for benefits decreased from $62,527,000 at the beginning of the year to $60,622,000 at the end of the year. The decrease is attributed to distributions and withdrawals exceeding total additions from net investment income and contributions. The...Show More

Bristol-Myers Squibb Company (BMY.US), a leading pharmaceutical company, has filed its annual Form 11-K with the Securities and Exchange Commission for the fiscal year ended December 31, 2023. The report details the financial performance of the Bristol-Myers Squibb Company Employee Incentive Thrift Plan, which is a defined contribution retirement plan for its employees. The plan includes a variety of investment options and is subject to ERISA provisions. The financial statements, audited by Withum Smith + Brown, PC, indicate that the plan's net assets available for benefits decreased from $62,527,000 at the beginning of the year to $60,622,000 at the end of the year. The decrease is attributed to distributions and withdrawals exceeding total additions from net investment income and contributions. The plan's investments are held in the Savings Plan Master Trust, which includes mutual funds, company stock, money market funds, and other assets. The report, signed by Senior Vice President and Treasurer Sandra Ramos-Alves on June 25, 2024, confirms the plan's compliance with U.S. GAAP and its tax-exempt status under the Code.